Source: PR NEWSWIRE

Press Release: Hapten Sciences : Hapten Sciences to Begin Clinical Trials for Novel Poison Ivy Vaccine

MEMPHIS, Tenn., Nov. 19, 2015 /PRNewswire/ -- Hapten Sciences, Inc., a privately held biotechnology company, announced today that it has filed an Investigational New Drug (IND) application and is now planning to initiate dosing of healthy volunteers in a first-in-human Phase 1...

Read full article »
Est. Annual Revenue
$5.0-25M
Est. Employees
25-100
Raymond J Hage's photo - President & CEO of Hapten Sciences

President & CEO

Raymond J Hage

CEO Approval Rating

85/100

Read more